Gut Microbiome and p-Inulin in CKD - TarGut CKD Study

Chronic Kidney Disease (CKD) is a condition in which the kidneys lose function over time. Research has shown that individuals with kidney disease have an altered gut microbiome, the microorganisms that live in the human gastrointestinal tract. This imbalance in the gut microbiome can aid in the progression of CKD. Research also indicates that treatment with prebiotics, special plant fibers that promote the growth of healthy bacteria in the GI tract, can help restore balance in the gut microbiome. However, more understanding is needed regarding variability in the performance and composition of the gut microbiome in individuals with CKD, and how this population can be impacted by interventions with prebiotic supplements.

The Gut Microbiome and p-Inulin in CKD (TarGut) Study was formed to determine if the gut microbiome of patients with CKD could be improved with treatment of p-inulin, a type of prebiotic. After recruitment and enrollment, TarGut participants are evaluated for a period of 28 weeks. This 28-week study period consists of three phases: an 8-week pre-treatment phase, 12-week active treatment phase, and 8-week post-treatment phase. During the active treatment phase participants take the p-inulin supplement daily, but participants don’t receive any intervention during the pre- and post-treatment phases. Biological samples are collected from study participants every week during the 28-week study period and assessed to determine microbial composition and function.